Vertex Pharmaceuticals Inc

1VRTX

Company Profile

  • Business description

    Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

  • Contact

    50 Northern Avenue
    BostonMA02210
    USA

    T: +1 617 341-6100

    E: [email protected]

    https://www.vrtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6,100

Stocks News & Analysis

stocks

Are small caps finally back?

Does renewed investor interest point to a structural shift in the underperforming factor?
stocks

Chart of the Week: Modest earnings growth at odds with overvalued bank shares

The latest update from our Industry Pulse report.
stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,321.1010.80-0.12%
CAC 408,206.8751.99-0.63%
DAX 4024,151.13178.90-0.74%
Dow JONES (US)46,590.41334.33-0.71%
FTSE 1009,515.0088.010.93%
HKSE25,781.77245.78-0.94%
NASDAQ22,740.40213.27-0.93%
Nikkei 22549,307.798.27-0.02%
NZX 50 Index13,306.4471.41-0.53%
S&P 5006,699.4035.95-0.53%
S&P/ASX 2009,030.0010.30-0.11%
SSE Composite Index3,913.762.57-0.07%

Market Movers